Title: 1 AN ACT relating to psychotropic drugs.
Official Title: 1 AN ACT relating to psychotropic drugs.
Number of Sections: 1
Source: versions - Introduced
Media Type: application/pdf
Strikethrough Detection: 7 sections found

================================================================================

Section 1:
UNOFFICIAL COPY 25 RS BR 1619
2 WHEREAS, in 2023, Kentucky's Medicaid program statistics showed 89,200
3 children and adolescents under the age of 18 being prescribed psychotropic drugs,
4 including 8,386 under the age of six; and
5 WHEREAS, the administration of nearly every psychotropic drug to children under
6 the age of six is off-label, meaning the drug is prescribed for age groups not approved by
7 the United States Food and Drug Administration (FDA); and
8 WHEREAS, psychotropic drugs, including stimulants, antidepressants,
9 antipsychotics, and other behavioral drugs, are being prescribed to children using
10 Medicaid funding and are documented by the FDA to include severe side effects,
11 including but not limited to addiction, suicidal ideation, aggression, hallucinations,
12 cardiovascular events, stunted growth, and developmental concerns; and
13 WHEREAS, parents and caregivers are frequently not informed of the FDA-
14 documented risks associated with the psychotropics being prescribed, including the
15 pediatric risks; and
16 WHEREAS, 21 C.F.R. sec. 208.20 establishes the requirements for an FDA
17 Medication Guide to provide easily understandable information about the risks and side
18 effects of prescription drugs for the average consumer, including parents and caregivers;
19 and
20 WHEREAS, according to the 21 C.F.R. sec. 208.20, a Medications Guide must
21 detail "the particular serious and significant public health concern that has created the
22 need for the Medication Guide"; note any known "pediatric risk"; include the risk of
23 "patients developing dependence on the drug products"; use a font size no smaller than
24 ten-point; be written in "nontechnical, understandable language"; and "not be
25 promotional in tone or content"; and
26 WHEREAS, to effectively monitor the effects of psychotropic drugs prescribed to
27 children and adolescents, particularly the FDA-cited "pediatric effects," parents and
Page 1 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 caregivers must be given a hard copy of the FDA Medication Guide for the psychotropic
2 drug being prescribed; and
3 WHEREAS, Medicaid is a state and federally funded program that provides
4 essential healthcare services to vulnerable populations, including children and
5 adolescents, it should be required to distribute the FDA Medication Guide to ensure
6 recipients and their guardians are fully informed of the risks and potential adverse effects
7 of psychotropic medications, thereby supporting informed consent and promoting patient
8 safety; and
9 WHEREAS, a reliable system for parents and caregivers to report adverse drug
10 reactions to psychotropic drugs is essential to help Medicaid agencies and legislators
11 monitor and assess the frequency, severity, and impact of such reactions within the public
12 sector; and
13 WHEREAS, the absence of an accessible, Medicaid-funded reporting mechanism
14 for drug side-effects limits the ability to identify and address these risks effectively,
15 compromising the safety of children and adolescents; and
16 WHEREAS, Medicaid is the primary payer for psychotropic medications prescribed
17 to children and adolescents in the public sector, including for off-label use in children
18 under the age of six, making it directly responsible for ensuring the safety and monitoring
19 of these prescriptions; and
20 WHEREAS, an adverse drug reaction (ADR) to psychotropic medications can have
21 significant physical, psychological, and developmental impacts on children, requiring
22 timely identification and response to mitigate harm; and
23 WHEREAS, the establishment of an online ADR reporting system would enable
24 Medicaid to fulfill its duty of care by providing a mechanism to collect critical safety
25 data, support evidence-based decision-making, and comply with its responsibility to
26 protect public health; and
27 WHEREAS, funding this reporting system aligns with Medicaid's obligations under
Page 2 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 federal law to monitor and improve the quality of care provided to its oversight and
2 accountability for the use of public funds in prescribing psychotropic medications; and
3 WHEREAS, the provisions of this Act are established to address these finding and
4 enhance oversight, informed consent, and accountability for children under the Medicaid
5 program;
6 NOW, THEREFORE,
7 Be it enacted by the General Assembly of the Commonwealth of Kentucky:
8 SECTION 1. A NEW SECTION OF KRS CHAPTER 205 IS CREATED TO
9 READ AS FOLLOWS:
10 (1) As used in this section:
11 (a) "Adverse drug reaction" or "ADR" means any unintended harmful
12 reaction or side effect to a psychotropic drug;
13 (b) "Child" means an individual under eighteen (18) years of age;
14 (c) "Medicaid-enrolled provider" means any licensed health professional
15 authorized to prescribe medication to Medicaid beneficiaries;
16 (d) "Medication Guide" means handouts accompanying certain prescription
17 medications with significant safety concerns as required under 21 C.F.R.
18 sec. 208.20;
19 (e) "Online reporting system" means a web-based platform through which
20 Medicaid beneficiaries or their parents or guardians can report ADRs
21 related to psychotropic drugs; and
22 (f) "Psychotropic drugs":
23 1. Means medications that affect the mind, emotions, or behavior of a
24 person, including but not limited to stimulants, antidepressants,
25 antipsychotics; and
26 2. Is limited to psychotropic drugs included on the Medicaid uniform
27 preferred drug list.
Page 3 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 (2) (a) A Medicaid-enrolled provider prescribing psychotropic drugs to a child
2 covered by Medicaid shall provide a Medication Guide to the child's parents
3 or legal guardians before issuing a prescription.
4 (b) The Medication Guide shall be printed and reviewed with the parent or
5 legal guardian to inform them of:
6 1. FDA-identified side effects and cautionary monitoring citations of
7 additional potential risks;
8 2. Any FDA black box warning detailing serious or life-threatening
9 risks; and
10 3. Pediatric-specific side effects or warnings related to children and
11 teens.
12 (3) A Medicaid-enrolled provider shall obtain written informed consent from the
13 parent or legal guardian before prescribing a psychotropic drug to a child
14 covered by Medicaid. The consent shall be:
15 (a) Signed by the parent or legal guardian, confirming that he or she:
16 1. Has received and reviewed the Medication Guide; and
17 2. Understands the associated risks and side effects of the psychotropic
18 drug; and
19 (b) Kept on file by the Medicaid-enrolled provider, with a copy provided to the
20 parent or legal guardian.
21 (4) (a) The cabinet shall, within twelve (12) months after the effective date of this
22 Act, develop and maintain a secure online reporting system of ADRs related
23 to psychotropic drugs prescribed to children and adolescents covered by
24 Medicaid.
25 (b) The system required under paragraph (a) of this subsection shall include
26 free text fields for the:
27 1. Name of patient;
Page 4 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 2. Name of medication;
2 3. Name of the person reporting;
3 4. Email address of the person reporting; and
4 5. Phone number of the person reporting.
5 (b) The System required under paragraph (a) of this subsection shall include
6 drop-down menus for the following:
7 1. Age of patient;
8 2. Class of psychotropic drug, including
9 a. Antidepressants;
10 b. Antipsychotics;
11 c. Mood stabilizers;
12 d. Stimulants;
13 e. Anti-anxiety drugs and sedatives;
14 f. Hypnotics; and
15 g. Unknown;
16 3. Type of adverse reaction experienced or observed, including:
17 a. Physical reaction, including:
18 i. Gastrointestinal issues, including nausea, vomiting,
19 diarrhea, or constipation;
20 ii. Neurological symptoms, including dizziness, headaches,
21 seizures, or tremors;
22 iii. Cardiovascular symptoms, including increased heart rate
23 or blood pressure changes; and
24 iv. Allergic reactions, rash, hives, or anaphylaxis;
25 b. Psychological reaction experienced or observed, including:
26 i. Mood changes, including irritability, depression, or
27 euphoria;
Page 5 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 ii. Anxiety or panic attacks;
2 iii. Hallucinations or delusions;
3 iv. Agitation or restlessness; and
4 v. Suicidal thoughts or behaviors; and
5 c. Behavioral reaction experienced or observed, including:
6 i. Sleep disturbances, including insomnia or hypersomnia;
7 ii. Increased aggression or hostility;
8 iii. Manic behaviors;
9 iv. Cognitive impairments, including memory loss or
10 confusion;
11 v. Self-harm; and
12 vi. Disassociation; and
13 4. Severity level of reaction, including:
14 a. Mild;
15 b. Moderate; and
16 c. Severe; and
17 5. Relation of person reporting, including:
18 a. Parent;
19 b. Foster parent;
20 c. Relative;
21 d. Legal guardian;
22 e. Case worker;
23 f. Social worker; and
24 g. Direct care staff.
25 (5) (a) The cabinet shall compile and submit a report no later than November 1,
26 2026, and each November 1 thereafter, summarizing ADR data related
27 to psychotropic drugs administered to children and adolescents
Page 6 of 7
XXXX 2/13/2025 11:55 AM Jacketed
UNOFFICIAL COPY 25 RS BR 1619
1 covered by Medicaid to the Legislative Research Commission for
2 referral to the Interim Joint Committees on Health Services and
3 Families and Children.
4 (b) The report shall include:
5 1. The number of ADRs reported categorized by patient age;
6 2. The totals of various severity levels of ADRs reported; and
7 2. A breakdown of ADRs by type of adverse reactions detailing the
8 number of incidents for each category.
9 (6) The cabinet shall submit a report no later than November 1, 2026, and each
10 November 1 thereafter summarizing implementation efforts and compliance
11 statistics of Medicaid-enrolled providers to the Legislative Research Commission
12 for referral to the Interim Joint Committees on Health Services and Families and
13 Children.
14 (7) Medicaid-enrolled providers failing to comply with the provisions of subsections
15 (2) and (3) of this section may face penalties, including but not limited to
16 termination of Medicaid enrollment.
17 (8) The cabinet shall promulgate administrative regulations in accordance with KRS
18 Chapter 13A to implement this section including the establishment of
19 enforcement mechanisms and appropriate penalties for violations.
Page 7 of 7
XXXX 2/13/2025 11:55 AM Jacketed
[DELETED:  C  2  J A W i 2 K M p s s 8 c a a u t a o 1 b p p d i W t t W p d i s a a a o b d a b p t c u M f a a d b t F t i s s e i b n l t a s i a h c W p a c a f n i o t F d r a w t p b p i t p W 2 C s 2 e t r f a F M e a W a t t 2 C s 2 d " p s a s p n f t M G n a k " r i t " t b w i " u l a " b p W c a a p t F " e p a]
[DELETED:  C  2  J c d W M i a s a f f p t p e h s t v p i c a a i s b r t d t F M G t e r o s W a r s f p a c t r a d r t p d i e t h M a a l m s W t f d s l t a t i a a t r e c W t c a a u o W s p p a d i o c r t W t e o M t f i d s d s e d a c w i r t p W]
[DELETED:  C  2  J f l t m a i t q o c p t i a W e p N B S R ( A ( " d r o " m a u h r ( " ( " p m a l h p a ( " G m h a c p m w s s c a r u 2 C s ( " r s m a w p t w M b o t p o g c r A r ( " 1 M m t a t m e o b o a p i b n l t s a a a 2   l t p d i o t M u p]
[DELETED:  C  2  J ( ( A M p p p d t a c c o ( T M G s b p a r w t p o l 1 F s e a c m c o a 2 A F b b w d s o l r 3 P s e o w r t c a t ( A M p s o w i c f t p o l g b p a p d t a c c ( S 1 H 2 U t a r a s e o t d ( K p ( ( T c A t p d p t c a a c b M ( T s r u p ( o t s s i f 1 N]
[DELETED:  C  2  J 2 N 3 N 4 E 5 P ( T S r u p ( o t d 1 A 2 C a A b A c M d S e A f H g U 3 T a P i G i i n v d i N s i d h s i C s i i h r o i A b P i M c i i d o e]
[DELETED:  C  2  J i A i H o i A v S c B i S i I i M i C i i m l o c v S v D 4 S a M b M c S 5 R a P b F c R d L e C f S g D ( ( T c s c a 2 t p d a t c a a]
[DELETED:  C  2  J c b M t t L R C f r t t I J C o H S a F ( T 1 T 2 T 2 A b o A b t o a r d t n ( T c s s a r n l t N 1 2 a e N 1 t s i e a c s o M p t f C ( M p f t c w t ( a ( o t s m f p i b n l t t ( T C 1 t i t s i t e o e]


================================================================================

Raw Text:
UNOFFICIAL COPY 25 RS BR 1619
1 AN ACT relating to psychotropic drugs.
2 WHEREAS, in 2023, Kentucky's Medicaid program statistics showed 89,200
3 children and adolescents under the age of 18 being prescribed psychotropic drugs,
4 including 8,386 under the age of six; and
5 WHEREAS, the administration of nearly every psychotropic drug to children under
6 the age of six is off-label, meaning the drug is prescribed for age groups not approved by
7 the United States Food and Drug Administration (FDA); and
8 WHEREAS, psychotropic drugs, including stimulants, antidepressants,
9 antipsychotics, and other behavioral drugs, are being prescribed to children using
10 Medicaid funding and are documented by the FDA to include severe side effects,
11 including but not limited to addiction, suicidal ideation, aggression, hallucinations,
12 cardiovascular events, stunted growth, and developmental concerns; and
13 WHEREAS, parents and caregivers are frequently not informed of the FDA-
14 documented risks associated with the psychotropics being prescribed, including the
15 pediatric risks; and
16 WHEREAS, 21 C.F.R. sec. 208.20 establishes the requirements for an FDA
17 Medication Guide to provide easily understandable information about the risks and side
18 effects of prescription drugs for the average consumer, including parents and caregivers;
19 and
20 WHEREAS, according to the 21 C.F.R. sec. 208.20, a Medications Guide must
21 detail "the particular serious and significant public health concern that has created the
22 need for the Medication Guide"; note any known "pediatric risk"; include the risk of
23 "patients developing dependence on the drug products"; use a font size no smaller than
24 ten-point; be written in "nontechnical, understandable language"; and "not be
25 promotional in tone or content"; and
26 WHEREAS, to effectively monitor the effects of psychotropic drugs prescribed to
27 children and adolescents, particularly the FDA-cited "pediatric effects," parents and
Page 1 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 caregivers must be given a hard copy of the FDA Medication Guide for the psychotropic
2 drug being prescribed; and
3 WHEREAS, Medicaid is a state and federally funded program that provides
4 essential healthcare services to vulnerable populations, including children and
5 adolescents, it should be required to distribute the FDA Medication Guide to ensure
6 recipients and their guardians are fully informed of the risks and potential adverse effects
7 of psychotropic medications, thereby supporting informed consent and promoting patient
8 safety; and
9 WHEREAS, a reliable system for parents and caregivers to report adverse drug
10 reactions to psychotropic drugs is essential to help Medicaid agencies and legislators
11 monitor and assess the frequency, severity, and impact of such reactions within the public
12 sector; and
13 WHEREAS, the absence of an accessible, Medicaid-funded reporting mechanism
14 for drug side-effects limits the ability to identify and address these risks effectively,
15 compromising the safety of children and adolescents; and
16 WHEREAS, Medicaid is the primary payer for psychotropic medications prescribed
17 to children and adolescents in the public sector, including for off-label use in children
18 under the age of six, making it directly responsible for ensuring the safety and monitoring
19 of these prescriptions; and
20 WHEREAS, an adverse drug reaction (ADR) to psychotropic medications can have
21 significant physical, psychological, and developmental impacts on children, requiring
22 timely identification and response to mitigate harm; and
23 WHEREAS, the establishment of an online ADR reporting system would enable
24 Medicaid to fulfill its duty of care by providing a mechanism to collect critical safety
25 data, support evidence-based decision-making, and comply with its responsibility to
26 protect public health; and
27 WHEREAS, funding this reporting system aligns with Medicaid's obligations under
Page 2 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 federal law to monitor and improve the quality of care provided to its oversight and
2 accountability for the use of public funds in prescribing psychotropic medications; and
3 WHEREAS, the provisions of this Act are established to address these finding and
4 enhance oversight, informed consent, and accountability for children under the Medicaid
5 program;
6 NOW, THEREFORE,
7 Be it enacted by the General Assembly of the Commonwealth of Kentucky:
8 SECTION 1. A NEW SECTION OF KRS CHAPTER 205 IS CREATED TO
9 READ AS FOLLOWS:
10 (1) As used in this section:
11 (a) "Adverse drug reaction" or "ADR" means any unintended harmful
12 reaction or side effect to a psychotropic drug;
13 (b) "Child" means an individual under eighteen (18) years of age;
14 (c) "Medicaid-enrolled provider" means any licensed health professional
15 authorized to prescribe medication to Medicaid beneficiaries;
16 (d) "Medication Guide" means handouts accompanying certain prescription
17 medications with significant safety concerns as required under 21 C.F.R.
18 sec. 208.20;
19 (e) "Online reporting system" means a web-based platform through which
20 Medicaid beneficiaries or their parents or guardians can report ADRs
21 related to psychotropic drugs; and
22 (f) "Psychotropic drugs":
23 1. Means medications that affect the mind, emotions, or behavior of a
24 person, including but not limited to stimulants, antidepressants,
25 antipsychotics; and
26 2. Is limited to psychotropic drugs included on the Medicaid uniform
27 preferred drug list.
Page 3 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 (2) (a) A Medicaid-enrolled provider prescribing psychotropic drugs to a child
2 covered by Medicaid shall provide a Medication Guide to the child's parents
3 or legal guardians before issuing a prescription.
4 (b) The Medication Guide shall be printed and reviewed with the parent or
5 legal guardian to inform them of:
6 1. FDA-identified side effects and cautionary monitoring citations of
7 additional potential risks;
8 2. Any FDA black box warning detailing serious or life-threatening
9 risks; and
10 3. Pediatric-specific side effects or warnings related to children and
11 teens.
12 (3) A Medicaid-enrolled provider shall obtain written informed consent from the
13 parent or legal guardian before prescribing a psychotropic drug to a child
14 covered by Medicaid. The consent shall be:
15 (a) Signed by the parent or legal guardian, confirming that he or she:
16 1. Has received and reviewed the Medication Guide; and
17 2. Understands the associated risks and side effects of the psychotropic
18 drug; and
19 (b) Kept on file by the Medicaid-enrolled provider, with a copy provided to the
20 parent or legal guardian.
21 (4) (a) The cabinet shall, within twelve (12) months after the effective date of this
22 Act, develop and maintain a secure online reporting system of ADRs related
23 to psychotropic drugs prescribed to children and adolescents covered by
24 Medicaid.
25 (b) The system required under paragraph (a) of this subsection shall include
26 free text fields for the:
27 1. Name of patient;
Page 4 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 2. Name of medication;
2 3. Name of the person reporting;
3 4. Email address of the person reporting; and
4 5. Phone number of the person reporting.
5 (b) The System required under paragraph (a) of this subsection shall include
6 drop-down menus for the following:
7 1. Age of patient;
8 2. Class of psychotropic drug, including
9 a. Antidepressants;
10 b. Antipsychotics;
11 c. Mood stabilizers;
12 d. Stimulants;
13 e. Anti-anxiety drugs and sedatives;
14 f. Hypnotics; and
15 g. Unknown;
16 3. Type of adverse reaction experienced or observed, including:
17 a. Physical reaction, including:
18 i. Gastrointestinal issues, including nausea, vomiting,
19 diarrhea, or constipation;
20 ii. Neurological symptoms, including dizziness, headaches,
21 seizures, or tremors;
22 iii. Cardiovascular symptoms, including increased heart rate
23 or blood pressure changes; and
24 iv. Allergic reactions, rash, hives, or anaphylaxis;
25 b. Psychological reaction experienced or observed, including:
26 i. Mood changes, including irritability, depression, or
27 euphoria;
Page 5 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 ii. Anxiety or panic attacks;
2 iii. Hallucinations or delusions;
3 iv. Agitation or restlessness; and
4 v. Suicidal thoughts or behaviors; and
5 c. Behavioral reaction experienced or observed, including:
6 i. Sleep disturbances, including insomnia or hypersomnia;
7 ii. Increased aggression or hostility;
8 iii. Manic behaviors;
9 iv. Cognitive impairments, including memory loss or
10 confusion;
11 v. Self-harm; and
12 vi. Disassociation; and
13 4. Severity level of reaction, including:
14 a. Mild;
15 b. Moderate; and
16 c. Severe; and
17 5. Relation of person reporting, including:
18 a. Parent;
19 b. Foster parent;
20 c. Relative;
21 d. Legal guardian;
22 e. Case worker;
23 f. Social worker; and
24 g. Direct care staff.
25 (5) (a) The cabinet shall compile and submit a report no later than November 1,
26 2026, and each November 1 thereafter, summarizing ADR data related
27 to psychotropic drugs administered to children and adolescents
Page 6 of 7
XXXX 2/13/2025 11:55 AM Jacketed

UNOFFICIAL COPY 25 RS BR 1619
1 covered by Medicaid to the Legislative Research Commission for
2 referral to the Interim Joint Committees on Health Services and
3 Families and Children.
4 (b) The report shall include:
5 1. The number of ADRs reported categorized by patient age;
6 2. The totals of various severity levels of ADRs reported; and
7 2. A breakdown of ADRs by type of adverse reactions detailing the
8 number of incidents for each category.
9 (6) The cabinet shall submit a report no later than November 1, 2026, and each
10 November 1 thereafter summarizing implementation efforts and compliance
11 statistics of Medicaid-enrolled providers to the Legislative Research Commission
12 for referral to the Interim Joint Committees on Health Services and Families and
13 Children.
14 (7) Medicaid-enrolled providers failing to comply with the provisions of subsections
15 (2) and (3) of this section may face penalties, including but not limited to
16 termination of Medicaid enrollment.
17 (8) The cabinet shall promulgate administrative regulations in accordance with KRS
18 Chapter 13A to implement this section including the establishment of
19 enforcement mechanisms and appropriate penalties for violations.
Page 7 of 7
XXXX 2/13/2025 11:55 AM Jacketed

[DELETED:  C  2  J A W i 2 K M p s s 8 c a a u t a o 1 b p p d i W t t W p d i s a a a o b d a b p t c u M f a a d b t F t i s s e i b n l t a s i a h c W p a c a f n i o t F d r a w t p b p i t p W 2 C s 2 e t r f a F M e a W a t t 2 C s 2 d " p s a s p n f t M G n a k " r i t " t b w i " u l a " b p W c a a p t F " e p a]
[DELETED:  C  2  J c d W M i a s a f f p t p e h s t v p i c a a i s b r t d t F M G t e r o s W a r s f p a c t r a d r t p d i e t h M a a l m s W t f d s l t a t i a a t r e c W t c a a u o W s p p a d i o c r t W t e o M t f i d s d s e d a c w i r t p W]
[DELETED:  C  2  J f l t m a i t q o c p t i a W e p N B S R ( A ( " d r o " m a u h r ( " ( " p m a l h p a ( " G m h a c p m w s s c a r u 2 C s ( " r s m a w p t w M b o t p o g c r A r ( " 1 M m t a t m e o b o a p i b n l t s a a a 2   l t p d i o t M u p]
[DELETED:  C  2  J ( ( A M p p p d t a c c o ( T M G s b p a r w t p o l 1 F s e a c m c o a 2 A F b b w d s o l r 3 P s e o w r t c a t ( A M p s o w i c f t p o l g b p a p d t a c c ( S 1 H 2 U t a r a s e o t d ( K p ( ( T c A t p d p t c a a c b M ( T s r u p ( o t s s i f 1 N]
[DELETED:  C  2  J 2 N 3 N 4 E 5 P ( T S r u p ( o t d 1 A 2 C a A b A c M d S e A f H g U 3 T a P i G i i n v d i N s i d h s i C s i i h r o i A b P i M c i i d o e]
[DELETED:  C  2  J i A i H o i A v S c B i S i I i M i C i i m l o c v S v D 4 S a M b M c S 5 R a P b F c R d L e C f S g D ( ( T c s c a 2 t p d a t c a a]
[DELETED:  C  2  J c b M t t L R C f r t t I J C o H S a F ( T 1 T 2 T 2 A b o A b t o a r d t n ( T c s s a r n l t N 1 2 a e N 1 t s i e a c s o M p t f C ( M p f t c w t ( a ( o t s m f p i b n l t t ( T C 1 t i t s i t e o e]